Background: Oxidative stress is reliably observed in major depressive disorder (MDD). However, molecular data on the principal cellular redox-sensitive transcriptional factors and the levels of their downstream-regulated antioxidant enzymes in MDD are scarce. Methods: In the peripheral blood mononuclear cells (PBMC) of subjects with a current episode of MDD (n = 30) and healthy controls (n = 35), we investigated alterations in the levels of redox-sensing nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein, its inhibitor Keap1, and nuclear factor-κB (NF-κB), along with their cognate downstream effectors, the antioxidant enzymes (AOEs): manganese and copper zinc superoxide dismutase (MnSOD and CuZnSOD, respectively), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GLR). Results: MDD subjects exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-κB in the cytoplasm of PBMC compared to controls. This state was further reflected by increased levels of MnSOD, CuZnSOD and CAT proteins and by the lack of correlation between MnSOD and CAT, which could indicate impaired oxidative detoxification capacity in MDD patients. Moreover, increased levels of MnSOD, CuZnSOD and CAT in MDD patients positively correlated with levels of Nrf2, while increased levels of SODs were also positively related to NF-κB. There were no differences regarding the levels of GPx and GLR proteins, but the ratio of GLR/GPx was reduced, suggesting diminished capacity of GPx in antioxidative defence in PBMC of MDD subjects. Conclusion: These data provide evidence that MDD is characterized by up-regulation of redox-sensitive transcriptional factors (Nrf2 and NF-κB) and AOEs (MnSOD, CuZnSOD and CAT), indicating pro-oxidative state in the PBMC of MDD patients.

Keywords:
Major depressive disorder, Nuclear factor (erythroid-derived 2)-like 2, Nuclear factor-κB, Antioxidative enzymes
1.
Ng F, Berk M, Dean O, Bush AI: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851-876.
2.
Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291-295.
3.
Maes M, Galecki P, Chang YS, Berk M: A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:676-692.
4.
Mates JM, Perez-Gomez C, Nunez de Castro I: Antioxidant enzymes and human diseases. Clin Biochem 1999;32:595-603.
5.
Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ: Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995;11:376-381.
6.
Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT: CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 2005;24:367-380.
7.
Gul M, Kutay FZ, Temocin S, Hanninen O: Cellular and clinical implications of glutathione. Indian J Exp Biol 2000;38:625-634.
8.
Harris ED: Regulation of antioxidant enzymes. FASEB J 1992;6:2675-2683.
9.
Lee JS, Surh YJ: Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005;224:171-184.
10.
Surh YJ, Kundu JK, Na HK: Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008;74:1526-1539.
11.
Baeuerle PA, Baltimore D: Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988;53:211-217.
12.
Schreck R, Albermann K, Baeuerle PA: Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992;17:221-237.
13.
Kobayashi M, Yamamoto M: Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 2006;46:113-140.
14.
Hoffmann A, Baltimore D: Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-186.
15.
Zhang R, Chae S, Lee JH, Hyun JW: The cytoprotective effect of butin against oxidative stress is mediated by the up-regulation of manganese superoxide dismutase expression through a PI3K/Akt/Nrf2-dependent pathway. J Cell Biochem 2012;113:1987-1997.
16.
Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, Stangl K: Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009;83:354-361.
17.
Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S: Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 2009;46:443-453.
18.
Lee JM, Calkins MJ, Chan KM, Kan YW, Johnson JA: Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278:12029-12038.
19.
Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A: Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci 2004;24:7324-7334.
20.
Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, St Clair DK: An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol 1999;18:709-722.
21.
Kim HT, Kim YH, Nam JW, Lee HJ, Rho HM, Jung G: Study of 5′-flanking region of human Cu/Zn superoxide dismutase. Biochem Biophys Res Commun 1994;201:1526-1533.
22.
Wan XS, Devalaraja MN, St Clair DK: Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol 1994;13:1127-1136.
23.
Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, Kap O, Yumru M, Savas HA, Akyol O: Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007;38:247-252.
24.
Sultana R, Perluigi M, Butterfield DA: Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006;8:2021-2037.
25.
Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O: Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001;64:43-51.
26.
Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R: Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003;8:365-370.
27.
Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007;22:67-73.
28.
Galecki P, Szemraj J, Bienkiewicz M, Florkowski A, Galecka E: Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009;61:436-447.
29.
Szuster-Ciesielska A, Slotwinska M, Stachura A, Marmurowska-Michalowska H, Dubas-Slemp H, Bojarska-Junak A, Kandefer-Szerszen M: Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:686-694.
30.
Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Seth PK, Srimal RC, Dikshit M: A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002;72:45-52.
31.
Kodydkova J, Vavrova L, Zeman M, Jirak R, Macasek J, Stankova B, Tvrzicka E, Zak A: Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009;42:1368-1374.
32.
Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O: Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19:89-95.
33.
Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett 2011;32:133-140.
34.
Michel TM, Frangou S, Thiemeyer D, Camara S, Jecel J, Nara K, Brunklaus A, Zoechling R, Riederer P: Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a postmortem study. Psychiatry Res 2007;151:145-150.
35.
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M: The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27-53.
36.
Gladkevich A, Kauffman HF, Korf J: Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:559-576.
37.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33; quiz 4-57.
38.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
39.
Simic I, Maric NP, Mitic M, Soldatovic I, Pavlovic Z, Mihaljevic M, Andric S, Radojcic MB, Adzic M: Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:281-285.
40.
Maric NP, Stojiljkovic DJ, Pavlovic Z, Jasovic-Gamsic M: Factors influencing the choice of antidepressants: a study of antidepressant prescribing practice at University Psychiatric Clinic in Belgrade. Vojnosanit Pregl 2012;69:308-313.
41.
Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with ‘mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
42.
Spiliotaki M, Salpeas V, Malitas P, Alevizos V, Moutsatsou P: Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients. Psychoneuroendocrinology 2006;31:748-760.
43.
Rybka J, Kupczyk D, Kedziora-Kornatowska K, Pawluk H, Czuczejko J, Szewczyk-Golec K, Kozakiewicz M, Antonioli M, Carvalho LA, Kedziora J: Age-related changes in an antioxidant defense system in elderly patients with essential hypertension compared with healthy controls. Redox Rep 2011;16:71-77.
44.
Radak Z, Chung HY, Naito H, Takahashi R, Jung KJ, Kim HJ, Goto S: Age-associated increase in oxidative stress and nuclear factor kappaB activation are attenuated in rat liver by regular exercise. FASEB J 2004;18:749-750.
45.
Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, Rahman I: Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008;10:799-811.
46.
Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F, Fuchs D, Oettl K: Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 2008;42:633-638.
47.
Kato T: Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 2007;21:1-11.
48.
Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P: Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res 2010;44:1267-1288.
49.
Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB: Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 2005;280:32485-32492.
50.
Kwak MK, Itoh K, Yamamoto M, Kensler TW: Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-2892.
51.
Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM: Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-1633.
52.
Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
53.
Schmidt HD, Shelton RC, Duman RS: Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011;36:2375-2394.
54.
Martin-de-Saavedra MD, Budni J, Cunha MP, Gomez-Rangel V, Lorrio S, Del Barrio L, Lastres-Becker I, Parada E, Tordera RM, Rodrigues AL, Cuadrado A, Lopez MG: Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 2013;38:2010-2022.
55.
Liu GH, Qu J, Shen X: NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 2008;1783:713-727.
56.
Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA: The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006;147:126-132.
57.
Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A: Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 1987;22:1349-1356.
58.
Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, McLoughlin DM, Meaney J, O'Keane V, Connor TJ: Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2012;2:e88.
59.
Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP: A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003;100:1920-1925.
60.
Lopresti AL, Maker GL, Hood SD, Drummond PD: A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:102-111.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.